Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Apollo Endosurgery, Inc.

APENNASDAQ
Healthcare
Medical - Devices
$10.00
$0.00(0.00%)
U.S. Market is Open • 15:51

Apollo Endosurgery, Inc. Fundamental Analysis

Apollo Endosurgery, Inc. (APEN) shows weak financial fundamentals with a PE ratio of -10.20, profit margin of -51.84%, and ROE of -84.92%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position14.02%
PEG Ratio-0.10
Current Ratio2.35

Areas of Concern

ROE-84.92%
Operating Margin-36.20%
We analyze APEN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -140.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-140.7/100

We analyze APEN's fundamental strength across five key dimensions:

Efficiency Score

Weak

APEN struggles to generate sufficient returns from assets.

ROA > 10%
-36.14%

Valuation Score

Excellent

APEN trades at attractive valuation levels.

PE < 25
-10.20
PEG Ratio < 2
-0.10

Growth Score

Weak

APEN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

APEN shows balanced financial health with some risks.

Debt/Equity < 1
1.75
Current Ratio > 1
2.35

Profitability Score

Weak

APEN struggles to sustain strong margins.

ROE > 15%
-8491.65%
Net Margin ≥ 15%
-51.84%
Positive Free Cash Flow
No

Key Financial Metrics

Is APEN Expensive or Cheap?

P/E Ratio

APEN trades at -10.20 times earnings. This suggests potential undervaluation.

-10.20

PEG Ratio

When adjusting for growth, APEN's PEG of -0.10 indicates potential undervaluation.

-0.10

Price to Book

The market values Apollo Endosurgery, Inc. at 12.47 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

12.47

EV/EBITDA

Enterprise value stands at -18.45 times EBITDA. This is generally considered low.

-18.45

How Well Does APEN Make Money?

Net Profit Margin

For every $100 in sales, Apollo Endosurgery, Inc. keeps $-51.84 as profit after all expenses.

-51.84%

Operating Margin

Core operations generate -36.20 in profit for every $100 in revenue, before interest and taxes.

-36.20%

ROE

Management delivers $-84.92 in profit for every $100 of shareholder equity.

-84.92%

ROA

Apollo Endosurgery, Inc. generates $-36.14 in profit for every $100 in assets, demonstrating efficient asset deployment.

-36.14%

Following the Money - Real Cash Generation

Operating Cash Flow

Apollo Endosurgery, Inc. generates limited operating cash flow of $-44.58M, signaling weaker underlying cash strength.

$-44.58M

Free Cash Flow

Apollo Endosurgery, Inc. generates weak or negative free cash flow of $-48.50M, restricting financial flexibility.

$-48.50M

FCF Per Share

Each share generates $-0.84 in free cash annually.

$-0.84

FCF Yield

APEN converts -5.87% of its market value into free cash.

-5.87%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-10.20

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.10

vs 25 benchmark

P/B Ratio

Price to book value ratio

12.47

vs 25 benchmark

P/S Ratio

Price to sales ratio

7.54

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.75

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.35

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.85

vs 25 benchmark

ROA

Return on assets percentage

-0.36

vs 25 benchmark

ROCE

Return on capital employed

-0.39

vs 25 benchmark

How APEN Stacks Against Its Sector Peers

MetricAPEN ValueSector AveragePerformance
P/E Ratio-10.2029.43 Better (Cheaper)
ROE-84.92%800.00% Weak
Net Margin-51.84%-20145.00% (disorted) Weak
Debt/Equity1.750.30 Weak (High Leverage)
Current Ratio2.354.64 Strong Liquidity
ROA-36.14%-17936.00% (disorted) Weak

APEN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Apollo Endosurgery, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ